A ten-year evolution of a multidrugresistant tuberculosis (MDR-TB) outbreak in an HIV-negative context, Tunisia ( )

Similar documents
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos

How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose

The Molecular Epidemiology of Tuberculosis

DNA FINGERPRINTING. Barry N. Kreiswirth, PhD Director, PHRI TB Center

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis

Qian Gao Fudan University

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

Diagnosis of drug resistant TB

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview

Ken Jost, BA, has the following disclosures to make:

Biomolecular diagnostics, gene sequencing and whole genome sequencing. Rob Warren

White Paper Application

Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No

Molecular Epidemiology and Clinical Characteristics of Drug-Resistant Mycobacterium tuberculosis in a Tuberculosis Referral Hospital in China

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao

Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province. Kgasha Matete Olga

Pyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

TB 101 Disease, Clinical Assessment and Lab Testing

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Discovery of a Novel Mycobacterium tuberculosis Lineage That Is a Major Cause of Tuberculosis in Rio de Janeiro, Brazil

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

Tuberculosis Elimination, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

Molecular Epidemiology of Tuberculosis: Current Insights

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida

Whole Genome Next Genera/on Sequencing of TB in a Public Health Laboratory: A New Diagnos/c Era

DRUG RESISTANCE IN TUBERCULOSIS

The nature and consequence of genetic variability within Mycobacterium tuberculosis

OUT-TB Web. Ontario Universal Typing of Tuberculosis: Surveillance and Communication System

Estimates for the mutation rates of spoligotypes and VNTR types of Mycobacterium tuberculosis

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

TB Intensive San Antonio, Texas November 11 14, 2014

Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa

Funding National Science and Technology Major Project, National Natural Science Foundation of China, and US National Insitutes of Health.

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis

Laboratory Diagnosis for MDR TB

TB Program and Epidemic aka B2B

TB trends and TB genotyping

Multi-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis

Treatment of Active Tuberculosis

M. tuberculosis as seen from M. avium.

Frances Jamieson, MD and Kevin May, BSc November 15 th,

Challenges in Capacity in SA for diagnosing DR-TB

Detection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Genomic Stability over 9 Years of an Isoniazid Resistant Mycobacterium tuberculosis Outbreak Strain in Sweden

Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD

Molecular Epidemiology of Extrapulmonary Tuberculosis

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Genomic structural variation

Human Genetics of Tuberculosis. Laurent Abel Laboratory of Human Genetics of Infectious Diseases University Paris Descartes/INSERM U980

General Session IV - Dale Schwab April 20, 2017

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

IHI Biomedical Sciences Group. Joseph Mugasa, PhD, PD. Stakeholders Meeting

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

Exploring the evolution of MRSA with Whole Genome Sequencing

Tuberculosis Past. Jaap T. van Dissel. National Institute for Public Health and the Environment RIVM Bilthoven The Netherlands

TB Nurse Case Management San Antonio, Texas April 9-11, 2013

Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria

ESCMID Online Lecture by author

VNTR . VNTR. VNTR. (Original Article) PCR-RFLP ( ETR-B, ETR-C, ETR-D, ETR-E, ETR-F : 7 .VNTR : : (Atypical Mycobacteria)

Signatures of Selection at Drug Resistance Loci in Mycobacterium tuberculosis. Caitlin S. Pepperell a,b

DRUG-RESISTANT TUBERCULOSIS

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

TB Control in Finland - the role of THL

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

Turning Off the Spigot Reducing Nosocomial Drug Resistant TB. Edward A. Nardell, MD Harvard Medical School/PIH Brigham & Women s Hospital

Evolution and transmission of drug resistant tuberculosis in a Russian population

Use of Whole Genome Sequencing to Determine the Microevolution of Mycobacterium tuberculosis during an Outbreak

NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Mycobacterium tuberculosis

Short Course Treatment for MDR TB

PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,

Patterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea

The epidemiology of tuberculosis

HIV replication and selection of resistance: basic principles

Experiment #1 TARGET Mouse Model Group. Report prepared by Paul Converse, Ph.D. and Eric Nuermberger, M.D. March 1, 2006

Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012

Multi-country surveillance project on fluoroquinolones and PZA resistance

Transcription:

A ten-year evolution of a multidrugresistant tuberculosis (MDR-TB) outbreak in an HIV-negative context, Tunisia (2001-2011) Naira Dekhil 1, Besma Mhenni 1, Raja Haltiti 2, and Helmi Mardassi 1 (speaker) 1 Unit of Typing & Genetics of Mycobacteria, Institut Pasteur de Tunis, Tunisia 2 Hôpital Régional de Menzel Bourguiba, Tunisia

MDR-TB outbreaks have been mainly described in HIV-positive institutionalized individuals Drug-sensitive and fitness-competent with an epidemic potential MTB clinical strain MDR-TB outbreak INH and RIF resistance-conferring mutations (MDR phenotype with fitness costs) HIV + community fitness fitness Acquisition of compensatory mutations HIV - community Could MDR-TB outbreaks emerge and expand in a community strictly negative for HIV?

An MDR-TB outbreak emerged in Tunisia and expanded in an HIV-negative context Mediterranean sea Bizerte 10 9 8 7 Tunisia Mediterranean sea N Cases s 6 5 4 3 2 1 0 ALGERIA 2001 2002 2003 2004 2005 2006 LIBYA

The Tunisian MDR-TB outbreak major characteristics The outbreak expanded in the general community (non institutionalized) Affected young (mean age ~27 yrs), immuno-competent and HIVnegative individuals The involved strains grow profisciently «in vitro» (Mardassi et al., EID 2005)

The Tunisian MDR-TB outbreak involved a Haarlem3 genotype clone harboring a rare rpob secondary site mutation, V615M Spoligoprofile IS6110 RFLP S531L V615M Mardassi et al., EID 2005

Development of a PCR-based test for the differentiation of the 12- and 11-banded profiles 12 11 GL-PCR Transposition site 12-banded 11-banded Rv0403c (mmps1) Rv0755c: Rv0755A + + + + Rv0963 + + Rv1645c: Rv1646 + - Rv1754c + + Rv2015c + + Rv2336 + + Rv2352c (PPE38) + + Rv2435c + + Rv2813: Rv2816 + + Rv2818c + + Rv3323c (moax) + + Namouchi et al., JID 2010 Namouchi& Mardassi, JMM 2006 Spacer31* + + Total 13 12

Identification of the closest drug-sensitive pre-outbreak strain Namouchi et al., JID 2010

Objectives Appreciate over a 10-year period (2001-2011) the clinical characteristics of the MDR-TB outbreak and the treatment outcome Carry out a comparative genomics analysis to better understand the molecualr basis undelying the epidemic phenotype Carry out an in-depth, 10-year spanning, genotypic analysis of the strains circulating in the epidemic region

The MDR-TB outbreak was more frequently associated with the 11-banded IS6110 RFLP profile 10 8 6 4 4 4 2 2 2 3 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 11-banded 11-banded 12-banded 12-banded

Aside from smear positivity, the 11- and 12- banded outbreak strains behave similarly Characteristics All outcomes N=45 (%) 11-banded IS6110RFLP N=35 12-banded IS6110RFLP N=10 MatchedOR (95% CI) P value (Pearson's Chisquare test) Age (years,means) 29,72 29,46 30,63 0,774 <20 ( 4 (8,89%) 3 1 1,19 (0,107-13,3) 0,887 20-40 27 (60%) 21 6 1 (0,163-6,138) 1 >40 5 (11,11%) 4 1 0,857 (0,082-8,965) 0,898 Male 40 (88,89) 31 9 0,861 (0,085-8,706) 0,899 Smear-positive 15 (33,33%) 9 (25,71%) 6 (60%) 4,333 (0,992-18,938) 0,043* epidemiological link 10 (22,22%) 8 2 0,633 (0,107-3,733) 0,612 Duration of treatment(months,means) 30,4 (67,56%) 29,83 32,4 0,81 Outcome category: Cure 17 (37,78%) 14 3 0,6 (0,120-3,007) 0,532 Failure 6 (13,33%) 5 1 0,657 (0,065-6,605) 0,72 Relapse 4 (8,89%) 4 0 0,750 (0,614-0,916) 0,257 Death 9 (20%) 5 4 4,6 (0,849-24,929) 0,064

Treatment outcome: The outbreak proved difficult to treat 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 12-banded 11-banded

Death was significantly associated with relapse and chronic cases Age, mean Smear positivity Relapse Death(N=9) P= 0,082 P= 0,197 P= 0,002 Matched OR (95% CI) 4 (0,431-3,7) Matched OR (95% CI) 0,052 (0,00562-0,492) % 11,11% 88,88%

Mutational analysis of drug resistance genes embb gidb gira rpob H37Rv genome (4 411 532 bp) rpsl rrs inha eis pnca katg

Evolution of the MDR-TB outbreak based on mutations in drug resistance genes

Genome sequencing using the Illumina platform 11-banded MDR H3 outbreak strain 2078 12-banded MDR H3 outbreak strain 1183 Susceptible genetically related H3 strain 233

Comparative genomics: Statistics Whole genome SNPs-based Venn diagram Whole genome LSPs-based Venn diagram Drug sensitive preoutbreak Drug sensitive preoutbreak 12 MDR Outbreak strains 44 23 12 8 MDR Outbreak strains SNP: Single Nucleotide Polymorphism LSP: Large Sequence Polymorphism( 10 bp)

Few Indel events differentiate other outbreak strains described worldwide Haarlem3 (Hamburg) N= 89 Outbreak (San Francisco) N=09 Beijing (Uzbekistan) N=02 5 SNPs + 5 short deletions 7 SNPs+0 indels 130 SNPs+ 1 large deletion (Andreas Roetzer,2013) Midori Kato-Maeda, 2013) (Niemann S, 2009)

0.0Mb 0.0Mb 4.4Mb 4.4Mb 1.1Mb 1.1Mb 3.3Mb 3.3Mb 2.2Mb 2.2Mb 0.0Mb 0.0Mb 4.4Mb 4.4Mb 1.1Mb 1.1Mb 3.3Mb 3.3Mb 2.2Mb 2.2Mb Indels contributed significantly to the clonal diversification of the MDR-TB outbreak-associated strains 0.1Mb 0.1Mb 0.2Mb 0.2Mb 4.3Mb 4.3Mb 4.2Mb 4.2Mb 0.3Mb 0.3Mb 4.1Mb 4.1Mb 0.4Mb 0.4Mb ssnp nssnp 4.0Mb 4.0Mb 0.5Mb 0.5Mb 3.9Mb 3.9Mb 0.6Mb 0.6Mb 3.8Mb 3.8Mb 0.7Mb 0.7Mb 3.7Mb 3.7Mb 0.8Mb 0.8Mb 3.6Mb 3.6Mb 0.9Mb 0.9Mb 3.5Mb 3.5Mb 1.0Mb 1.0Mb 3.4Mb 3.4Mb 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1.2Mb 1.2Mb 3.2Mb 3.2Mb 1.3Mb 1.3Mb 3.1Mb 3.1Mb 1.4Mb 1.4Mb 3.0Mb 3.0Mb 1.5Mb 1.5Mb 2.9Mb 2.9Mb 1.6Mb 1.6Mb 2.8Mb 2.8Mb 1.7Mb 2.7Mb 1.7Mb 2.7Mb 1.8Mb 1.8Mb 2.6Mb 2.6Mb 1.9Mb 1.9Mb 2.5Mb 2.5Mb 2.0Mb 2.0Mb 2.4Mb 2.4Mb 2.1Mb 2.1Mb 2.3Mb 2.3Mb 0.1Mb 0.1Mb 0.2Mb 4.3Mb 0.2Mb 4.3Mb 4.2Mb intergenic indels 1: TUN2412-10 2: TUN1923-01 3: TUN1843-08 4: TUN228-02 5: TUN2078-03 6: TUN1183-02 7: TUN233-02 4.2Mb 0.3Mb 0.3Mb 4.1Mb 4.1Mb 0.4Mb 0.4Mb 4.0Mb 4.0Mb 0.5Mb 0.5Mb 3.9Mb 3.9Mb 0.6Mb 0.6Mb 3.8Mb 3.8Mb 0.7Mb 0.7Mb 3.7Mb 3.7Mb 0.8Mb 0.8Mb 3.6Mb 3.6Mb 0.9Mb 0.9Mb 3.5Mb 3.5Mb 1.0Mb 1.0Mb 3.4Mb 3.4Mb 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1.2Mb 1.2Mb 3.2Mb 3.2Mb 1.3Mb 1.3Mb 3.1Mb 3.1Mb 1.4Mb 1.4Mb 3.0Mb 3.0Mb 1.5Mb 2.9Mb 1.5Mb 2.9Mb 1.6Mb 1.6Mb 2.8Mb 2.8Mb 1.7Mb 1.7Mb 2.7Mb 2.7Mb 1.8Mb 1.8Mb 2.6Mb 2.6Mb 1.9Mb 1.9Mb 2.5Mb 2.5Mb 2.0Mb 2.4Mb 2.0Mb 2.4Mb 2.1Mb 2.1Mb 2.3Mb 2.3Mb

Genome-wide-based Maximum Likelihood phylogenetic tree

What have we learned from microgenomics on the biology of the MDR-TB outbreak?

Comparative genomics coupled to structural analysis disclosed the possible role of the rpob secondary mutation, V615M, in fitness cost compensation No putative compensatory mutations either in rpoc or in rpoa coud be identified V615M maps to the flexible bridge helix structure which interact with DNA

The outbreak-restricted secondary site rpob mutation, V615M, did indeed restore the fitness costs of S531L 1,2 SM WT DM 1 Relative Fitness 0,8 0,6 0,4 0,2 Engineered mutant BCG harboring V615M +S531L grows as efficiently as WT-BCG ) 0 BCG S531L S531L&V615M Engineered mutant BCG harboring V615M +S531L and WT-BCG display comparable fitness

An in-frame deletion in the ferredoxin gene is likely to be critical to the epidemic potential of the Tunisian MDR outbreak strain 400 pb 1081 pb 680 pb

Shared, outbreak-restricted, deletions to be further explored by functional genetics 1.9 kb I I I 1 kb 4.7 kb

Main outputs from comparative genomics Phylogenomics confirm the relatedness of the Tunisian MDR- TB outbreak strain with the epidemic CDC1551 and C strains The genome of the MDR-TB outbreak strain appears to evolve rapidly, mainly through frequent indel events Rationale comparative genomics identified key deletion events which could have contributed to the epidemic phenotype of the Tunisian MDR outbreak strain

An in-depth snapshot of the molecular epidemiology of the M. tuberculosis Haarlem genotype in the epidemic region

All Haarlem strains and variants co-evolving with the MDR-TB outbreak (2001-2011) were included in a MIRU-VNTR24 typing analyses N=45 MDR-TB N=182 Haarlem3 Sit 50 N=242 strains 2001-2011 N=47 Haarlem1 Sit 47 N=5 Orphan N=197 non MDR-TB N=4 Haarlem3 Sit 03 N=02 Haarlem3 Sit 36 N=02 Haarlem3 Sit963

The MTB Haarlem strain family, northern Tunisia, is likely to be intrinsically epidemic and genetically unstable N=35 N=30 N=53 MDR-TB outbreak Recent transmission rate: 86% N=45

Conclusions MDR-TB outbreaks can emerge and successfully expand in a HIVnegative context Evolution to the XDR phenotype is likely to be a associated with the genetic trait of the involved strain rather than treatment default The Tunisian MDR-TB outbreak benefited of an intrinsic epidemic potential coupled to a rapid genomic evolution, mainly through indels